ZA200200462B - Biodegradable poly (alkylene oxide)-poly (p-dioxanone) block copolymer soluble in organic solvents, and drug delivery composition comprising same. - Google Patents

Biodegradable poly (alkylene oxide)-poly (p-dioxanone) block copolymer soluble in organic solvents, and drug delivery composition comprising same. Download PDF

Info

Publication number: ZA200200462B
Authority: ZA; South Africa
Prior art keywords: poly; block copolymer; copolymer; block; dioxanone
Prior art date: 1999-07-20

Application number

ZA200200462A

Other languages

English (en)

Inventor

In-Ja Choi

Min-Hyo Seo

Original Assignee

Samyang Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-20

Filing date

2002-01-18

Publication date

2003-03-26

2002-01-18 Application filed by Samyang Corp filed Critical Samyang Corp

2003-03-26 Publication of ZA200200462B publication Critical patent/ZA200200462B/en

Links

229920001400 block copolymer Polymers 0.000 title claims abstract description 53
239000000203 mixture Substances 0.000 title claims abstract description 33
229920002463 poly(p-dioxanone) polymer Polymers 0.000 title claims abstract description 14
239000003960 organic solvent Substances 0.000 title claims abstract description 12
238000012377 drug delivery Methods 0.000 title abstract description 11
125000002947 alkylene group Chemical group 0.000 title description 2
-1 poly(p-dioxanone) Polymers 0.000 claims abstract description 68
229920000233 poly(alkylene oxides) Polymers 0.000 claims abstract description 16
229920001577 copolymer Polymers 0.000 claims description 34
VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims description 24
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 20
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
229920000359 diblock copolymer Polymers 0.000 claims description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
230000002209 hydrophobic effect Effects 0.000 claims description 12
239000012867 bioactive agent Substances 0.000 claims description 10
239000004310 lactic acid Substances 0.000 claims description 10
235000014655 lactic acid Nutrition 0.000 claims description 10
108090000623 proteins and genes Proteins 0.000 claims description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
102000004169 proteins and genes Human genes 0.000 claims description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
229920005604 random copolymer Polymers 0.000 claims description 6
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 6
239000003242 anti bacterial agent Substances 0.000 claims description 5
238000009472 formulation Methods 0.000 claims description 5
239000003102 growth factor Substances 0.000 claims description 5
229920001519 homopolymer Polymers 0.000 claims description 5
239000004005 microsphere Substances 0.000 claims description 5
239000000178 monomer Substances 0.000 claims description 5
239000002077 nanosphere Substances 0.000 claims description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
239000002260 anti-inflammatory agent Substances 0.000 claims description 4
229940088710 antibiotic agent Drugs 0.000 claims description 4
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
229940088597 hormone Drugs 0.000 claims description 4
239000005556 hormone Substances 0.000 claims description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
239000000693 micelle Substances 0.000 claims description 4
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 3
108060001064 Calcitonin Proteins 0.000 claims description 3
102000055006 Calcitonin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
102000004877 Insulin Human genes 0.000 claims description 3
102000014150 Interferons Human genes 0.000 claims description 3
108010050904 Interferons Proteins 0.000 claims description 3
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
230000001741 anti-phlogistic effect Effects 0.000 claims description 3
229960004015 calcitonin Drugs 0.000 claims description 3
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
229960005309 estradiol Drugs 0.000 claims description 3
229930182833 estradiol Natural products 0.000 claims description 3
239000000835 fiber Substances 0.000 claims description 3
239000010408 film Substances 0.000 claims description 3
229940125396 insulin Drugs 0.000 claims description 3
229940079322 interferon Drugs 0.000 claims description 3
239000003094 microcapsule Substances 0.000 claims description 3
229960005486 vaccine Drugs 0.000 claims description 3
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 2
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
108010036949 Cyclosporine Proteins 0.000 claims description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
229920005682 EO-PO block copolymer Polymers 0.000 claims description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
229930182566 Gentamicin Natural products 0.000 claims description 2
108060003199 Glucagon Proteins 0.000 claims description 2
108010069236 Goserelin Proteins 0.000 claims description 2
108010000521 Human Growth Hormone Proteins 0.000 claims description 2
102000002265 Human Growth Hormone Human genes 0.000 claims description 2
239000000854 Human Growth Hormone Substances 0.000 claims description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
229930012538 Paclitaxel Natural products 0.000 claims description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
239000004098 Tetracycline Substances 0.000 claims description 2
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 2
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
229960003942 amphotericin b Drugs 0.000 claims description 2
230000003115 biocidal effect Effects 0.000 claims description 2
210000004556 brain Anatomy 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
229960004562 carboplatin Drugs 0.000 claims description 2
190000008236 carboplatin Chemical compound 0.000 claims description 2
230000010261 cell growth Effects 0.000 claims description 2
229960001265 ciclosporin Drugs 0.000 claims description 2
229960003405 ciprofloxacin Drugs 0.000 claims description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
229960004316 cisplatin Drugs 0.000 claims description 2
229930182912 cyclosporin Natural products 0.000 claims description 2
229960001259 diclofenac Drugs 0.000 claims description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
229960004679 doxorubicin Drugs 0.000 claims description 2
229960003722 doxycycline Drugs 0.000 claims description 2
210000002919 epithelial cell Anatomy 0.000 claims description 2
210000003743 erythrocyte Anatomy 0.000 claims description 2
229940011871 estrogen Drugs 0.000 claims description 2
239000000262 estrogen Substances 0.000 claims description 2
229960002949 fluorouracil Drugs 0.000 claims description 2
229940028334 follicle stimulating hormone Drugs 0.000 claims description 2
235000019253 formic acid Nutrition 0.000 claims description 2
229960002518 gentamicin Drugs 0.000 claims description 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
229960004666 glucagon Drugs 0.000 claims description 2
229960003690 goserelin acetate Drugs 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
238000002513 implantation Methods 0.000 claims description 2
229960000905 indomethacin Drugs 0.000 claims description 2
229960004125 ketoconazole Drugs 0.000 claims description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
229960000991 ketoprofen Drugs 0.000 claims description 2
210000000265 leukocyte Anatomy 0.000 claims description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 2
229960004338 leuprorelin Drugs 0.000 claims description 2
229960000485 methotrexate Drugs 0.000 claims description 2
229960004023 minocycline Drugs 0.000 claims description 2
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims description 2
239000002088 nanocapsule Substances 0.000 claims description 2
229960001699 ofloxacin Drugs 0.000 claims description 2
230000002642 osteogeneic effect Effects 0.000 claims description 2
229960001592 paclitaxel Drugs 0.000 claims description 2
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
229960002702 piroxicam Drugs 0.000 claims description 2
229960003387 progesterone Drugs 0.000 claims description 2
239000000186 progesterone Substances 0.000 claims description 2
238000007920 subcutaneous administration Methods 0.000 claims description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
229960003604 testosterone Drugs 0.000 claims description 2
229960002180 tetracycline Drugs 0.000 claims description 2
229930101283 tetracycline Natural products 0.000 claims description 2
235000019364 tetracycline Nutrition 0.000 claims description 2
150000003522 tetracyclines Chemical class 0.000 claims description 2
229920000428 triblock copolymer Polymers 0.000 claims description 2
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical group C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 2
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 1
241000283690 Bos taurus Species 0.000 claims 1
102000051325 Glucagon Human genes 0.000 claims 1
108010016076 Octreotide Proteins 0.000 claims 1
101000868144 Sus scrofa Somatotropin Proteins 0.000 claims 1
239000013583 drug formulation Substances 0.000 claims 1
230000012010 growth Effects 0.000 claims 1
238000010253 intravenous injection Methods 0.000 claims 1
229960002700 octreotide Drugs 0.000 claims 1
229920001451 polypropylene glycol Polymers 0.000 claims 1
229940079593 drug Drugs 0.000 description 26
239000003814 drug Substances 0.000 description 26
229920000642 polymer Polymers 0.000 description 26
238000000034 method Methods 0.000 description 14
229920000117 poly(dioxanone) Polymers 0.000 description 14
238000002360 preparation method Methods 0.000 description 13
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 9
229920001427 mPEG Polymers 0.000 description 8
229920000747 poly(lactic acid) Polymers 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 8
239000002904 solvent Substances 0.000 description 7
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
229920002988 biodegradable polymer Polymers 0.000 description 6
239000004621 biodegradable polymer Substances 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000007943 implant Substances 0.000 description 5
229920000954 Polyglycolide Polymers 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
JQZRVMZHTADUSY-UHFFFAOYSA-L di(octanoyloxy)tin Chemical compound [Sn+2].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O JQZRVMZHTADUSY-UHFFFAOYSA-L 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229920001477 hydrophilic polymer Polymers 0.000 description 3
229920001600 hydrophobic polymer Polymers 0.000 description 3
239000000463 material Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
239000013543 active substance Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
238000005227 gel permeation chromatography Methods 0.000 description 2
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000000047 product Substances 0.000 description 2
239000008279 sol Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
102000009025 Endorphins Human genes 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
108010079943 Pentagastrin Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
108010086019 Secretin Proteins 0.000 description 1
102100037505 Secretin Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
229920001963 Synthetic biodegradable polymer Polymers 0.000 description 1
108010012944 Tetragastrin Proteins 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000002416 angiotensin derivative Substances 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
230000000578 anorexic effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000002456 anti-arthritic effect Effects 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
230000001139 anti-pruritic effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940124346 antiarthritic agent Drugs 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
229940124538 antidiuretic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
229940005486 antimigraine preparations Drugs 0.000 description 1
239000002579 antinauseant Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000012620 biological material Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
150000003842 bromide salts Chemical class 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229940037530 cough and cold preparations Drugs 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
230000001592 luteinising effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229920006030 multiblock copolymer Polymers 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000002445 parasympatholytic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960000444 pentagastrin Drugs 0.000 description 1
ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
239000003450 potassium channel blocker Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
238000007151 ring opening polymerisation reaction Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
229960002101 secretin Drugs 0.000 description 1
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
229940064707 sympathomimetics Drugs 0.000 description 1
RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
SQBBHCOIQXKPHL-UHFFFAOYSA-N tributylalumane Chemical compound CCCC[Al](CCCC)CCCC SQBBHCOIQXKPHL-UHFFFAOYSA-N 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
VOITXYVAKOUIBA-UHFFFAOYSA-N triethylaluminium Chemical compound CC[Al](CC)CC VOITXYVAKOUIBA-UHFFFAOYSA-N 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
238000009736 wetting Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
235000004416 zinc carbonate Nutrition 0.000 description 1
239000011667 zinc carbonate Substances 0.000 description 1
229910000010 zinc carbonate Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nanotechnology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
Dispersion Chemistry (AREA)
Optics & Photonics (AREA)
Chemical Kinetics & Catalysis (AREA)
Polymers & Plastics (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Polyesters Or Polycarbonates (AREA)

ZA200200462A 1999-07-20 2002-01-18 Biodegradable poly (alkylene oxide)-poly (p-dioxanone) block copolymer soluble in organic solvents, and drug delivery composition comprising same. ZA200200462B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR1019990029269A KR20010010393A (ko)	1999-07-20	1999-07-20	소수성 고분자와 친수성 고분자의 생분해성 블록 공중합체 및이를 포함하는 약물 전달체 조성물

Publications (1)

Publication Number	Publication Date
ZA200200462B true ZA200200462B (en)	2003-03-26

Family

ID=19602907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200200462A ZA200200462B (en)	1999-07-20	2002-01-18	Biodegradable poly (alkylene oxide)-poly (p-dioxanone) block copolymer soluble in organic solvents, and drug delivery composition comprising same.

Country Status (14)

Country	Link
US (1)	US6599519B1 (fr)
EP (1)	EP1196149B1 (fr)
JP (1)	JP3955759B2 (fr)
KR (2)	KR20010010393A (fr)
CN (1)	CN1205248C (fr)
AT (1)	ATE468848T1 (fr)
AU (1)	AU758838B2 (fr)
BR (1)	BRPI0012588B8 (fr)
CA (1)	CA2379672C (fr)
DE (1)	DE60044459D1 (fr)
MX (1)	MXPA02000600A (fr)
NZ (1)	NZ517035A (fr)
WO (1)	WO2001005379A1 (fr)
ZA (1)	ZA200200462B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6201072B1 (en) *	1997-10-03	2001-03-13	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
WO2002085337A1 (fr)	2001-04-20	2002-10-31	The University Of British Columbia	Systemes d'administration de medicament micellaire pour medicaments hydrophobes
US7217770B2 (en) *	2000-05-17	2007-05-15	Samyang Corporation	Stable polymeric micelle-type drug composition and method for the preparation thereof
US6362308B1 (en) *	2000-08-10	2002-03-26	Alkermes Controlled Therapeutics Inc. Ii	Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
ES2326209T3 (es)	2000-10-27	2009-10-05	Baxter Healthcare S.A.	Produccion de microesferas.
GB0029750D0 (en) *	2000-12-06	2001-01-17	Laporte Performance Chemicals	Alkylene oxide-lactone copolymers
JP2004517127A (ja)	2000-12-21	2004-06-10	ネクターセラピューティックス	ポリエン抗真菌剤の肺送達
KR100773078B1 (ko) *	2001-06-21	2007-11-02	주식회사 삼양사	결정성이 높은 난용성 약물을 함유하는 고분자 미셀형약물 조성물
KR100508369B1 (ko) *	2001-10-31	2005-08-17	주식회사 바이오폴리메드	펩타이드 스페이서를 갖는 생체적합성 고분자
JP4290381B2 (ja) *	2002-04-11	2009-07-01	学校法人聖マリアンナ医科大学	ピリドンカルボン酸化合物含有エマルション
PT1532985T (pt) *	2002-06-25	2017-01-20	Takeda Pharmaceuticals Co	Processo de produção de uma composição de libertação sustentada
KR100502840B1 (ko) *	2002-09-04	2005-07-21	학교법인 포항공과대학교	약물 담지능력이 우수한 블록 공중합체 미셀 조성물
JP2006516548A (ja) *	2002-12-30	2006-07-06	アンジオテックインターナショナルアクツィエンゲゼルシャフト	迅速ゲル化ポリマー組成物からの薬物送達法
JPWO2005018607A1 (ja) *	2003-08-20	2007-11-01	味の素株式会社	溶解性を改善した医薬品製剤
KR100597845B1 (ko)	2004-12-29	2006-07-10	호남석유화학 주식회사	폴리파라다이옥산온의 제조방법
WO2007067624A2 (fr) *	2005-12-06	2007-06-14	Tyco Healthcare Group Lp	Composes bioabsorbables et compositions les contenant
EP2086513B1 (fr) *	2006-09-26	2016-09-07	Samyang Biopharmaceuticals Corporation	Nanoparticule submicronique de dérivés de camptothécine faiblement solubles dans l'eau et son procédé de préparation
EP1920765A1 (fr) *	2006-11-07	2008-05-14	Medigene AG	Procédé de préparation des liposomes en une seule passe
JP5613679B2 (ja)	2009-10-21	2014-10-29	日本化薬株式会社	腹腔内投与用の抗がん剤含有ブロック共重合体、ミセル調製物及びそれを有効成分とする癌治療薬
US20110237686A1 (en)	2010-03-26	2011-09-29	Cerulean Pharma Inc	Formulations and methods of use
KR101335624B1 (ko) *	2011-02-08	2013-12-02	이화여자대학교 산학협력단	졸-겔 전이 키토산-폴리머 복합체 및 그의 용도
BR112014012444B1 (pt)	2011-11-23	2021-12-14	Therapeuticsmd, Inc	Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
CA2878680C (fr)	2012-07-23	2019-09-17	Crayola, Llc	Films pouvant etre dissous et procedes d'utilisation de ces derniers
US20150202313A1 (en) *	2012-08-31	2015-07-23	New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery	Macromolecular Prodrugs for Hard Tissue and Methods of Use Thereof
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9949928B2 (en) *	2013-05-01	2018-04-24	The Regents Of The University Of Colorado, A Body Corporate	Biodegradable copolymers, systems including the copolymers, and methods of forming and using same
CA2947767A1 (fr)	2014-05-22	2015-11-26	Therapeuticsmd, Inc.	Formulations d'hormones substitutives combinees naturelles et traitement hormonal substitutif
KR101501217B1 (ko)	2014-07-17	2015-03-10	최명	필러용 폴리디옥사논 입자의 제조방법
WO2016094594A1 (fr)	2014-12-09	2016-06-16	Sweetwater Energy, Inc.	Prétraitement rapide
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (fr)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
WO2017173071A1 (fr)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Composition pharmaceutique d'hormone stéroïde
WO2018110870A1 (fr) *	2016-12-14	2018-06-21	주식회사 삼양바이오팜	Composition de copolymère séquencé amphiphile à stabilité micellaire améliorée et composition pharmaceutique la comprenant
WO2018151833A1 (fr)	2017-02-16	2018-08-23	Sweetwater Energy, Inc.	Formation de zone à haute pression pour le prétraitement
WO2019030412A1 (fr) *	2017-08-11	2019-02-14	Ferring B.V.	Procédé de fabrication d'une préparation pharmaceutique
KR102013041B1 (ko)	2017-12-21	2019-08-21	포항공과대학교 산학협력단	항암제가 담지된 나노구조체를 유효성분으로 포함하는 간암 치료용 약학조성물
KR102093660B1 (ko) *	2019-07-08	2020-03-26	(주)리젠바이오참	온도감응형 조직유착 방지용 하이드로겔 조성물 및 그 제조방법
AU2020357419B2 (en) *	2019-10-01	2025-12-04	InnoCore Technologies Holding B.V.	Biodegradable, phase separated, thermoplastic multi-block copolymer
EP4077490A1 (fr)	2019-12-22	2022-10-26	Sweetwater Energy, Inc.	Procédés de fabrication de lignine et de produits de lignine spécialisés à partir de biomasse
KR102365597B1 (ko) *	2019-12-24	2022-02-18	성균관대학교산학협력단	에멀젼 조성물, 그리고 이를 포함하는 약물 조성물 및 화장품용 조성물
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4052988A (en)	1976-01-12	1977-10-11	Ethicon, Inc.	Synthetic absorbable surgical devices of poly-dioxanone
US4643191A (en)	1985-11-29	1987-02-17	Ethicon, Inc.	Crystalline copolymers of p-dioxanone and lactide and surgical devices made therefrom
US5019094A (en)	1990-05-09	1991-05-28	Ethicon, Inc.	Crystalline copolymers of p-dioxanone and poly(alkylene oxides)
US5080665A (en)	1990-07-06	1992-01-14	American Cyanamid Company	Deformable, absorbable surgical device
US5352515A (en) *	1992-03-02	1994-10-04	American Cyanamid Company	Coating for tissue drag reduction
US5522841A (en) *	1993-05-27	1996-06-04	United States Surgical Corporation	Absorbable block copolymers and surgical articles fabricated therefrom

1999
- 1999-07-20 KR KR1019990029269A patent/KR20010010393A/ko active Pending
2000
- 2000-07-18 KR KR10-2001-7001936A patent/KR100431491B1/ko not_active Expired - Fee Related
- 2000-07-18 CN CNB008105375A patent/CN1205248C/zh not_active Expired - Lifetime
- 2000-07-18 BR BRPI0012588A patent/BRPI0012588B8/pt not_active IP Right Cessation
- 2000-07-18 WO PCT/KR2000/000779 patent/WO2001005379A1/fr not_active Ceased
- 2000-07-18 MX MXPA02000600A patent/MXPA02000600A/es active IP Right Grant
- 2000-07-18 CA CA002379672A patent/CA2379672C/fr not_active Expired - Lifetime
- 2000-07-18 DE DE60044459T patent/DE60044459D1/de not_active Expired - Lifetime
- 2000-07-18 JP JP2001510436A patent/JP3955759B2/ja not_active Expired - Fee Related
- 2000-07-18 NZ NZ517035A patent/NZ517035A/en not_active IP Right Cessation
- 2000-07-18 EP EP00946497A patent/EP1196149B1/fr not_active Expired - Lifetime
- 2000-07-18 AU AU60247/00A patent/AU758838B2/en not_active Expired
- 2000-07-18 US US09/763,921 patent/US6599519B1/en not_active Expired - Lifetime
- 2000-07-18 AT AT00946497T patent/ATE468848T1/de not_active IP Right Cessation
2002
- 2002-01-18 ZA ZA200200462A patent/ZA200200462B/en unknown

Also Published As

Publication number	Publication date
KR20020008815A (ko)	2002-01-31
AU758838B2 (en)	2003-04-03
EP1196149A4 (fr)	2004-04-21
BR0012588B1 (pt)	2013-02-19
MXPA02000600A (es)	2002-07-02
KR20010010393A (ko)	2001-02-05
JP2003504393A (ja)	2003-02-04
EP1196149A1 (fr)	2002-04-17
WO2001005379A1 (fr)	2001-01-25
US6599519B1 (en)	2003-07-29
BR0012588A (pt)	2002-04-09
CA2379672A1 (fr)	2001-01-25
ATE468848T1 (de)	2010-06-15
CN1205248C (zh)	2005-06-08
EP1196149B1 (fr)	2010-05-26
NZ517035A (en)	2003-07-25
CA2379672C (fr)	2005-03-22
KR100431491B1 (ko)	2004-05-14
DE60044459D1 (de)	2010-07-08
AU6024700A (en)	2001-02-05
BRPI0012588B8 (pt)	2021-05-25
CN1361684A (zh)	2002-07-31
JP3955759B2 (ja)	2007-08-08

Publication	Publication Date	Title
CA2379672C (fr)	2005-03-22	Bloc copolymere d'oxyde de polyalkylene-poly(p-dioxanone) biodegradable soluble dans des solvants organiques et composition le contenant permettant de distribuer un medicament
AU763154B2 (en)	2003-07-17	Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof
AU2002222733B2 (en)	2006-03-30	Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
AU2002303027C1 (en)	2006-06-01	Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug
CA2345659C (fr)	2010-09-21	Copolymeres trisequences de polyester polyethyleneglycol, de faible poids moleculaire, biodegradables et dotes de caracteristiques inverses de gelification thermique
JP5121790B2 (ja)	2013-01-16	薬剤送達のための生物分解性ブロックコポリマー組成物
AU2002222733A1 (en)	2002-08-22	Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
JP2002516910A (ja)	2002-06-11	逆熱的ゲル化特性を有する生分解性低分子量トリブロックポリ（ラクチド−ｃｏ−グリコリド）−ポリエチレングリコールコポリマー
ZA200102453B (en)	2001-09-28	Biodegradable low molecular weight triblock polyester polythylene glycol copolymers having reverse thermal gelation properties.
US7226616B2 (en)	2007-06-05	Positively charged amphiphilic block copolymer as drug carrier and complex thereof with negatively charged drug
JP2007513970A (ja)	2007-05-31	薬剤用の可溶化剤としての生分解性トリブロックコポリマー類およびそれらの使用方法
AU2002319922A1 (en)	2003-05-22	Positively charged amphiphilic block copolymer as drug carrier and complex thereof with negatively charged drug
MXPA01003316A (en)	2002-07-25	Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties